Management and Treatment of Ascending Aortic Aneurysm

Indications for Surgical Intervention

• The American College of Cardiology recommends surgical intervention for patients with ascending aortic aneurysm when the diameter reaches 5.5 cm or greater in patients with degenerative thoracic aneurysm, and at smaller diameters (4.0-5.0 cm) for patients with genetic disorders such as Marfan syndrome, Loeys-Dietz syndrome, or bicuspid aortic valve 1, 2
• Earlier intervention at smaller diameters (4.0-5.0 cm) is recommended for patients with Marfan syndrome, Loeys-Dietz syndrome, bicuspid aortic valve, and familial thoracic aortic aneurysm and dissection 2, 3
• Concomitant repair of the aortic root or replacement of the ascending aorta should be considered when patients undergo aortic valve repair/replacement and have an ascending aorta or aortic root >4.5 cm 2, 3

Growth Rate Criteria

• Surgical intervention should be considered when growth rate exceeds 0.5 cm/year, even if the aorta is less than 5.5 cm in diameter 2, 3

Symptomatic Patients

• Prompt surgical intervention is recommended for patients with symptoms suggestive of aneurysm expansion, unless life expectancy is limited or quality of life is substantially impaired 1, 2

Other Risk Factors

• Lower thresholds for intervention may be considered in cases of growth of aortic diameter ≥3 mm per year, resistant hypertension, short stature (<1.69 m), root phenotype, aortic length >11 cm, age <50 years, desire for pregnancy, or aortic coarctation 4

Surgical Techniques

• Resection and graft replacement is the most commonly performed and recommended procedure for isolated ascending aortic aneurysms 1
• For isolated dilatation of the ascending tubular (supra-coronary) aorta, a supra-commissural tubular graft is inserted with the distal anastomosis just before the aortic arch 5
• Aortic valve-sparing techniques, such as the David procedure (reimplantation) or Yacoub technique (remodelling with aortic annuloplasty), may be recommended for patients with pliable aortic valve cusps 4, 5
• Composite replacement of the aortic root and valve with the Bentall procedure is indicated for patients with non-salvageable aortic valves 5

Medical Management

• Optimal implementation of cardiovascular risk management and medical treatment are recommended to reduce major adverse cardiovascular events in patients with aortic aneurysms 5, 6

Surveillance Recommendations

• After surgical repair, follow-up imaging is essential, with first follow-up imaging within 1 post-operative year, and every 5 years thereafter if findings are stable 4
• Annual TTE monitoring is recommended for patients with bioprosthetic valves 5

Important Considerations and Pitfalls

• Endovascular stent grafts have not been approved by the FDA for treatment of aneurysms or conditions of the ascending aorta 1, 7
• Fluoroquinolones should generally be avoided in patients with aortic aneurysms but may be considered if there is a compelling clinical indication and no other reasonable alternative 5, 6
• Aortic diameter is the major criterion for recommending elective operation, but other factors such as family history, genetic disorders, and symptoms should be considered in the decision-making process 1, 2, 4

Management of Ascending Aortic Aneurysm Symptoms

Immediate Actions for Symptomatic Patients

• Initiate medical therapy immediately while arranging surgical evaluation, including aggressive blood pressure control, heart rate control (target <60 bpm with beta-blockers preferred), and pain management, as recommended by the European Society of Cardiology 8
• Obtain cross-sectional imaging (CT angiography or cardiac MRI) to define anatomy, measure precise diameter, and assess for complications like dissection or impending rupture, as suggested by the European Heart Journal 8

Surveillance After Symptom Resolution or Surgery

• For medically managed patients (asymptomatic, subthreshold size): imaging every 6-12 months depending on diameter and growth rate, as recommended by the European Heart Journal 8
• Screen first-degree relatives with aortic imaging, as familial clustering is common, according to the European Heart Journal 8

Surgical Approach for Symptomatic Cases

• Operative mortality for elective ascending aortic surgery is 1-3% at experienced centers, far lower than the mortality from rupture or dissection in symptomatic patients, as reported by the European Heart Journal [9] [10]

Management of Ascending Thoracic Aortic Aneurysm

Primary Surgical Management Team

• The American College of Cardiology recommends that cardiothoracic surgeons with specialized expertise in aortic surgery manage ascending aortic aneurysms, as these lesions require open surgical repair with cardiopulmonary bypass, hypothermic circulatory arrest, and complex reconstruction techniques, with optimal outcomes achieved at centers performing these procedures regularly 11, 12

Referral Criteria to Cardiovascular Surgery

• Immediate surgical referral is mandatory for symptomatic patients with chest pain, back pain, dyspnea, hoarseness, or dysphagia attributable to the aneurysm, regardless of size, as recommended by the American Heart Association 11
• The American College of Cardiology suggests earlier surgical evaluation (at 4.0-5.0 cm) for Loeys-Dietz syndrome patients (surgery at 4.2-4.6 cm) 11

Surgical Techniques Requiring Specialized Expertise

• The American College of Cardiology recommends that cardiovascular surgeons be proficient in partial or total arch replacement when aneurysm extends into the arch, requiring hypothermic circulatory arrest and cerebral perfusion strategies, as described in the Circulation journal 12, 13

Critical Pitfalls to Avoid

• The American Heart Association advises against delaying referral of symptomatic patients, as symptoms indicate impending rupture or dissection with mortality rates exceeding 50% if untreated, with an operative mortality for elective surgery at experienced centers of 1-5% 11
• The American College of Cardiology recommends against relying solely on absolute diameter thresholds without considering patient height and body surface area, and against using endovascular stent grafts for ascending aortic aneurysms, as they are not FDA-approved for this location 11, 12

Management of Fusiform Ascending Thoracic Aortic Aneurysm

Immediate Surgical Indications

• The American College of Cardiology recommends prompt surgical intervention for patients with symptoms attributable to the aneurysm, such as chest pain, back pain, dyspnea, hoarseness, or dysphagia, regardless of aortic diameter, as symptoms indicate impending rupture or dissection with mortality rates exceeding 50% if untreated 14

Size-Based Surgical Thresholds for Asymptomatic Patients

• The European Society of Cardiology recommends surgery at ≥5.5 cm maximum diameter when performed at experienced centers with operative mortality <5% 14, 15
• The American College of Cardiology recommends composite replacement of the aortic root and valve with the Bentall procedure for patients with non-salvageable aortic valves, with operative mortality of 2.2% at experienced centers 14

Surgical Techniques

• The European Heart Journal recommends valve-sparing aortic root replacement in patients with aortic root dilatation if performed in experienced centers, using techniques such as the David procedure or Yacoub technique 15
• The American College of Cardiology recommends lifelong vitamin K antagonists for all patients with a Bentall procedure using a mechanical heart valve prosthesis 15

Extension into Aortic Arch

• The American College of Cardiology recommends extending the repair with a hemiarch replacement during open surgical repair of the ascending aorta if aneurysmal disease extends into the proximal aortic arch 14

Medical Management

• The European Heart Journal recommends optimal implementation of cardiovascular risk management and medical treatment to reduce major adverse cardiovascular events in all patients with aortic aneurysms 15

Surveillance Strategy

• The European Heart Journal recommends assessment of the entire aorta at baseline and during follow-up when a thoracic aortic aneurysm is identified 15
• The European Heart Journal recommends cardiac CT or cardiac MRI to confirm transthoracic echocardiography measurements, rule out aortic asymmetry, and determine baseline diameters for follow-up 15

Management of Thoracic Aortic Aneurysm

Surgical Intervention Thresholds

• The European Society of Cardiology recommends surgical repair for thoracic aortic aneurysms when the ascending aorta reaches ≥5.5 cm in degenerative disease, or at smaller thresholds (4.0-5.0 cm) in genetic syndromes, with endovascular repair (TEVAR) preferred over open surgery for descending thoracic aneurysms when anatomy is suitable 16
• Surgery is indicated at ≥5.5 cm for degenerative aneurysms with tricuspid aortic valve, as recommended by the European Society of Cardiology 17
• Earlier intervention at 4.0-5.0 cm is required for Loeys-Dietz syndrome (specifically 4.2-4.6 cm), as stated by the Mayo Clinic Proceedings 18
• Elective repair at ≥5.5 cm is recommended for non-heritable disease in the descending thoracic aorta, according to the European Heart Journal 16, 17
• TEVAR is preferred over open repair when anatomy is suitable, as recommended by the European Heart Journal 16, 17
• Repair is recommended at ≥6.0 cm in low-moderate surgical risk patients with thoracoabdominal aortic aneurysm, according to the European Heart Journal 16, 17

Surgical Techniques by Location

• Valve-sparing root replacement (David or Yacoub procedure) is recommended for pliable valve cusps at experienced centers, as stated by the Mayo Clinic Proceedings and European Heart Journal 17, 18
• Bentall procedure (composite root and valve replacement) is recommended for non-salvageable valves, requiring lifelong vitamin K antagonists if mechanical valve used, according to the European Heart Journal 17
• Supracoronary tubular graft is recommended for isolated ascending involvement above sinotubular junction, as stated by the Mayo Clinic Proceedings 18
• Hemiarch or total arch replacement is recommended depending on the extent of involvement, according to the Mayo Clinic Proceedings 18
• TEVAR is first-line when anatomy is suitable for descending thoracic aorta, as recommended by the European Heart Journal 16, 17
• Revascularize left subclavian artery before TEVAR if coverage planned, to reduce spinal cord ischemia and stroke risk, according to the European Heart Journal 16, 17

Medical Management

• All patients with thoracic aortic aneurysm require aggressive cardiovascular risk reduction, including strict blood pressure control, beta-blockers, statin therapy, and avoidance of fluoroquinolones, as recommended by the European Heart Journal 17

Surveillance Strategy

• Transthoracic echocardiography (TTE) is recommended at diagnosis for aortic valve and root assessment, according to the European Heart Journal 17
• Cardiac CT or cardiac MRI is recommended for ascending aorta, arch, descending thoracic, and TAAA surveillance, as stated by the European Heart Journal 17
• TTE is not adequate for distal ascending, arch, or descending aorta monitoring, according to the European Heart Journal 17
• After open repair, CT is recommended within 1 month, then yearly for 2 years, then every 5 years if stable, as stated by the European Heart Journal 17
• After TEVAR, imaging is recommended at 1 month and 12 months, then yearly, according to the European Heart Journal 17

Critical Pitfalls to Avoid

• TEVAR should not be used in genetic/connective tissue disorders, as contraindicated for elective intervention, according to the Mayo Clinic Proceedings 18
• Refer to high-volume multidisciplinary aortic centers, as outcomes are significantly better with experienced teams, as stated by the Mayo Clinic Proceedings 18

Guideline Recommendations for Rapidly Growing Thoracic Aortic Aneurysm

Pharmacologic Management

Indications for Surgical Intervention

Imaging and Surveillance

Emergency Evaluation

Management of Ascending Aorta and Aortic Root Dilation – Guideline Summary

Initial Imaging and Measurement

• The European Society of Cardiology (ESC) recommends obtaining cardiac‑gated CT or MRI with centerline measurements at the annulus, sinuses of Valsalva, sinotubular junction, and mid‑ascending aorta; measurements must be taken perpendicular to flow to avoid over‑estimation. 23
• The ESC states that transthoracic echocardiography (TTE) is sufficient for initial screening of the aortic root and proximal ascending aorta but is inadequate for the distal ascending aorta, arch, or descending aorta. 23
• When TTE cannot reliably assess aortic root or ascending aorta morphology, the ESC requires cardiac MRI or CT for definitive evaluation. [23][24]
• Any TTE measurement showing a diameter > 50 mm or growth > 3 mm / year must be confirmed with CT or MRI before a surgical decision is made, per ESC guidance. 23
• The ESC advises against indexing aortic diameter to body surface area except in extreme body‑size variations; an aortic cross‑sectional area/height ratio ≥ 10 cm²/m warrants surgical consideration. [25][26]

Risk Stratification

Genetic and Syndromic Conditions

• All patients should be screened for heritable thoracic aortic disease because these conditions lower surgical thresholds and trigger family screening (ESC). [23][27]24
• In Marfan syndrome, the ESC recommends surgery when the aortic diameter reaches 4.0–5.0 cm, depending on additional risk factors (Class IIa). 24
• For Loeys‑Dietz syndrome, surgery is advised at 4.2–4.6 cm (≥ 45 mm) on CT/MRI (Class IIa, ESC). 27
• ACTA2‑related disease warrants surgery at ≥ 45 mm, or at lower thresholds if other risk factors are present (ESC). [27][24]
• Patients with bicuspid aortic valve (BAV) should undergo surgery at ≥ 50 mm for isolated aortopathy, or at ≥ 45 mm when concomitant valve surgery is planned (ESC & American Heart Association [AHA]). [23][24]28

High‑Risk Modifiers (Lower Threshold to 5.0 cm in Non‑Syndromic Patients)

Surveillance Imaging Intervals

• For aortic diameters ≥ 4.0 cm, the ESC recommends imaging every 6–12 months using the same modality and centerline technique. [23][28]
• When the diameter is ≥ 4.5 cm or growth exceeds 3 mm / year, annual imaging is advised (ESC). 23

Surgical Intervention Thresholds

Degenerative / Non‑Syndromic Disease (Tricuspid Aortic Valve)

• Surgery is indicated at a maximum diameter ≥ 5.5 cm (Class I, ESC & AHA). [23][25]26
• Surgery is reasonable at ≥ 5.0 cm when performed by experienced surgeons in a multidisciplinary aortic team and additional risk factors are present (Class IIa, ESC). [25][26]
• For isolated tubular ascending aorta in low‑risk patients, surgery is reasonable at > 5.2 cm (Class IIa, ESC). [24][26]

Bicuspid Aortic Valve Disease

• Surgery is indicated at ≥ 5.0 cm for isolated BAV aortopathy when any high‑risk modifier (coarctation, hypertension, family history, growth > 3 mm/yr) exists (Class I, ESC). [23][24]
• In low‑risk BAV patients, surgery is reasonable at ≥ 5.0 cm for the ascending phenotype, or at ≥ 4.5 cm when valve surgery is concurrently planned (Class IIa, ESC & AHA). [23][24]28
• During aortic valve replacement in BAV patients, replacement of the ascending aorta is recommended at ≥ 4.5 cm (Class IIa, ESC). [23][24]28

Concomitant Cardiac Surgery

• When aortic valve repair or replacement (tricuspid or bicuspid) is performed, ascending aortic replacement is reasonable at ≥ 4.5 cm if an experienced multidisciplinary team is involved (Class IIa, ESC). [23][25]26
• For other cardiac operations (e.g., coronary bypass) without valve work, ascending aortic replacement may be reasonable at ≥ 5.0 cm (Class IIa, AHA). 25

Growth‑Based Indications

• Surgery is mandated when the aortic diameter grows ≥ 0.5 cm in a single year, irrespective of absolute size (Class I, AHA). 25
• Surgery is mandated when growth ≥ 0.3 cm per year persists over two consecutive years (Class I, AHA). 25

Symptomatic Aneurysm

• Immediate surgery is required for any aneurysm‑related symptoms (chest/back pain, dyspnea, hoarseness, dysphagia) regardless of diameter, as untreated symptomatic disease carries > 50 % mortality (Class I, AHA & ESC). [25][26]

Medical Management

• Aggressive cardiovascular risk reduction is advised: strict blood‑pressure control, statin therapy targeting LDL‑C < 1.4 mmol/L, and avoidance of fluoroquinolones (ESC). [24][26]
• In patients with polyvascular disease who are symptomatic and not at high bleeding risk, the ESC suggests rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily. 24

Family Screening

• First‑degree relatives should undergo TTE to assess for BAV and aortic dilation; BAV prevalence among relatives is 9–20 % (AHA). 28
• When a heritable thoracic aortic disease is suspected but no pathogenic variant is identified, screening should start at age 25 or 10 years younger than the earliest affected family member (whichever is earlier), then repeat every 5 years until age 60 (ESC). 23
• If a relative is found to have BAV or aortic dilation, cascade screening of other family members is recommended (AHA). 28

Surgical Technique Recommendations

• Valve‑sparing aortic root replacement (David reimplantation or Yacoub remodeling) is recommended for patients with pliable valve cusps when performed at experienced centers (ESC). 26
• Composite root and valve replacement (Bentall procedure) is indicated for non‑salvageable valves; lifelong vitamin K antagonist therapy is required if a mechanical valve is used (ESC). 26
• Hemiarch replacement is reasonable when aneurysmal disease extends into the proximal arch > 50 mm, and may be considered at > 45 mm in high‑volume centers (ESC). 26

Post‑Operative Surveillance

• After open surgical repair, obtain a contrast‑enhanced CT at 1 month, again at 1 year, and subsequently every 5 years if stable (ESC). 26
• For patients who had isolated aortic valve surgery with an ascending aorta > 40 mm, perform TTE at 1 year and then every 2–3 years if stable (ESC). [23][24]

Referral and Multidisciplinary Care

• The AHA advises referral of all patients with ascending aortic disease to high‑volume multidisciplinary aortic teams; outcomes are markedly better when experienced surgeons perform these procedures (Class I). 25